Clinical trials: Primary
Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol…
- Conditions
- Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol
- Trial name
- SPIRIT (NCT04807400)
- Testing
- Inclisiran, Behavioural Support, Background lipid lowering therapy
- Where
- 17 sites in United Kingdom
- Volunteers
- 892 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
CKD-828 Primary Hypertension Trial(Dose-selection)
The aim of this trial is to determine the best dose combination of S-Amlodipine and Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a once daily regimen of various combinations of…
- Trial name
- NCT01128322
- Testing
- S-Amlodipine, Telmisartan, S-Amlodipine, Telmisartan
- Where
- 26 sites in South Korea
- Volunteers
- 430 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Episodic Cluster Headache, Chronic Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL…
- Trial name
- NCT02797951
- Testing
- Galcanezumab
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus (Type 2), Prediabetes
Evaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality
Primary objective: To evaluate the effectiveness of the ARISE strategy on the proportion of individuals with confirmed T2DM diagnosis, per protocol criteria based on the PCDT-DM2 (Clinical Protocol and Therapeutic Guidelines for…
- Trial name
- ARISE (NCT07846319)
- Testing
- ARISE Strategy
- Where
- 2 sites in Brazil
- Volunteers
- 45,000 people, healthy volunteers welcome
- Sponsor
- epHealth
Enthesitis-related Arthritis (ERA), Juvenile Psoriatic Arthritis (JPsA)
Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.
The goal of this study is to understand the long-term treatment strategies in children and adolescents diagnosed with ERA or JPsA who received secukinumab and achieved inactive disease and to evaluate the long-term treatment…
- Trial name
- NCT07190053
- Testing
- Secukinumab
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Primary Insomnia
A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia
- Trial name
- NCT00209937
- Testing
- Gaboxadol
- Volunteers
- 675 people
- Sponsor
- H. Lundbeck A/S
Hereditary Angioedema
Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema
The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent hereditary angioedema attacks.
- Trial name
- NCT04687137
- Testing
- TAK-743 300 mg
- Where
- 9 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Takeda
Primary Open-angle Glaucoma, Ocular Hypertension
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control…
- Trial name
- NCT03419975
- Testing
- TJO-002, Latanoprost
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Hypercholesterolemia
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lowering effect and dose-response of…
- Trial name
- NCT00404001
- Testing
- MD-0727
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Hypercholesterolemia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia
- Trial name
- NCT06717360
- Testing
- AG2304T, AG2304R
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression…
- Trial name
- FIRST (NCT03602859)
- Testing
- Niraparib, Dostarlimab (TSR-042), Standard of care
- Where
- 182 sites in United States, Belarus and 17 more
- Volunteers
- 1,400 people
- Sponsor
- Tesaro, Inc.
Open-angle Glaucoma
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
- Trial name
- NCT03488550
- Testing
- ANX007
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annexon, Inc.
Myeloproliferative Neoplasms
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
- Trial name
- NCT07008118
- Testing
- INCA035784
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF)…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Trial name
- NCT02124746
- Testing
- Momelotinib
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 87 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Open Angle Glaucoma
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
- Trial name
- NCT06223048
- Testing
- AMDX-2011P
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amydis Inc.
Primary Hypercholesterolemia
Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia
To determine the efficacy of the HS-25 (10mg or 20mg) or in combination with Atorvastatin (10mg)in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary…
- Trial name
- HS-25-C-01 (NCT03464682)
- Testing
- HS-25 10mg, HS-25 10mg combination with Atorvastatin, HS-25 20mg combination with Atorvastatin
- Volunteers
- 720 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Migraine
Safety, Efficacy and Pharmacokinetics of ALD403
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.
- Trial name
- NCT01772524
- Testing
- ALD403
- Where
- 26 sites in United States
- Volunteers
- 163 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Aspergillosis, Invasive Pulmonary Aspergillosis
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.
- Conditions
- Aspergillosis, Invasive Pulmonary Aspergillosis, Neuroaspergillosis
- Trial name
- NCT01188759
- Testing
- Voriconazole, Anidulafungin
- Sponsor
- Pfizer
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Advanced Solid Tumours, Breast Cancer
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03507543
- Testing
- IMP4297
- Where
- 3 sites in Australia
- Volunteers
- 39 people
- Sponsor
- Impact Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.